Travere Therapeutics just misses on confirmatory study for kidney disease drug, stock plummets - Endpoints News
endpts.comSubmitted by endpointsnews6292 in business
Travere Therapeutics’ kidney disease drug narrowly failed its confirmatory study seven months after it won accelerated approval. Travere said Thursday it still intends to apply for full approval of Filspari in IgA nephropathy in the first half of next year, m…